Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins.
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Export pumps often limit the usefulness of anticancer drugs. Here we investigated the effect of cisplatin on the expression of ABC proteins in human colon cancer cells. Short-term incubation of Caco-2 and LS174T cells with cisplatin resulted in up-regulation of several ABC pumps, in particular MRP2 and BCRP. In partially cisplatin-resistant cells (LS174T/R) obtained by long-term exposure to cisplatin, MRP2 and BCRP up-regulation was more marked. This was further enhanced when these cells were cultured under maintained stimulation with cisplatin. The MRP2 promoter (MRP2pr) was cloned, and partially deleted constructs linked to reporter genes were generated. Transfection of LS174T and LS174T/R cells with these constructs revealed the ability of cisplatin to activate MRP2pr. The intensity of this response was dependent on the conserved MRP2pr region. Basal MRP2pr activity was higher in LS174T/R cells, in which the expression of the transcription factors c/EBPβ, HNF1α, HNF3β, and HNF4α, but not PXR, p53, c-Myc, AP1, YB-1, NRF2, and RARα was enhanced. Up-regulation was particularly high for FXR (200-fold) and SHP (50-fold). In LS174T/R cells, GW4064 induced the expression of FGF19, SHP, OSTα/β, but not MRP2 and BCRP, although the sensitivity of these cells to cisplatin was further reduced. In LS174T cells, GW4064-induced chemoresistance was seen only after being transfected with FXR+RXR, when BCRP, but not MRP2, was up-regulated. Protection of LS174T cells against cisplatin was mimicked by transfection with BCRP. In conclusion, in colon cancer cells, cisplatin treatment enhances chemoresistance through FXR-dependent and FXR-independent mechanisms involving the expression of BCRP and MRP2, respectively.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Markwell, M. A. K., Haas, S. M., Bieber, L. L., & Tolbert, N. E. (1978) · Analytical Biochemistry · doi:10.1016/0003-2697(78)90586-9 · Cited by 6,458
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M., & Edwards, P. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109326200 · Cited by 916
Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J., Juijn, J. A., Baas, F., & Borst, P. (1997) · PubMed · Cited by 882
Cisplatin and platinum drugs at the molecular level (Review)
Boulikas, T., & Vougiouka, M. (2003) · Oncology Reports · doi:10.3892/or.10.6.1663 · Cited by 729
Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
Chin, K.-V., Ueda, K., Pastan, I., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726
Cui, Y., König, J., Buchholz, U., Spring, H., Leier, I., & Keppler, D. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23190-4 · Cited by 676
Research works printed but not linked: 8
- Boulikas T., 2003, Oncol. Rep., 10, 1663
- Samimi G., 2003, Clin. Cancer Res., 9, 5853
- Komatsu M., 2000, Cancer Res., 60, 1312
- Hinoshita E., 2000, Clin. Cancer Res., 6, 2401
- Kool M., 1997, Cancer Res., 57, 3537
- Koike K., 1997, Cancer Res., 57, 5475
- Wang Q., 1998, Cancer Res., 58, 5762
- To K. K., 2011, Mol. Carcinog., 51, 449
Cited by
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Vaquero, J., Monte, M. J., Domínguez, M., Muntané, J., & Marín, J. J. G. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.022 · Cited by 139
“In this respect, it is noteworthy that FXR-dependent expression of target genes involved in chemoresistance are different in intestinal (ABCC2 and ABCG2) [14] and liver (ABCB4, TCEA2, CCL14, CCL15 and KRT13) [15] cells.”
BackgroundSelf-citationMultidrug efflux transporter ABCG2: expression and regulation
Kukal, S., Guin, D., Rawat, C., Bora, S., Mishra, M., Sharma, P., Paul, P. R., Kanojia, N., Grewal, G. K., Kukreti, S., et al. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03901-y · Cited by 139
Nuclear bile acid signaling through the farnesoid X receptor
Mazuy, C., Helleboid‐Chapman, A., Staels, B., & Lefèbvre, P. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1805-y · Cited by 122
“[145, 146] reported that FXR activation stimulates the chemoprotection of hepatocytes against genotoxic compounds, thus reducing the response of tumor cells to pharmacologically induced cellular toxicity in vitro.”
BackgroundmiR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy
Tan, S., Shi, H., Ba, M., LIN, S., Tang, H., Zeng, X., & Zhang, X. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2492 · Cited by 112
“Researchers are actively engaged in elucidating the mechanisms responsible for resistance to treatment in aim to identify and develop strategies to overcome it, not only in colon cancer, but also in other types of malignant disease (7).”
DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death
Low, H. B., Wong, Z. L., Wu, B., Kong, L. R., Png, C. W., Cho, Y.-L., Li, C., Xiao, F., Xin, X., Yang, H. H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22638-7 · Cited by 88
Wang, X. J., Li, Y., Luo, L., Wang, H., Chi, Z., Xin, A., Li, X., Wu, J., & Tang, X. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.02.010 · Cited by 87
Gumulec, J., Balvan, J., Sztalmachová, M., Raudenská, M., Dvořáková, V., Knopfová, L., Polanska, H. H., Hudcová, K., Ruttkay-Nedecký, B., Babula, P., et al. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2223 · Cited by 80
Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer
Girisa, S., Henamayee, S., Parama, D., Rana, V., Dutta, U., & Kunnumakkara, A. B. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00035-2 · Cited by 66
“ACR: Acyclic retinoid; ADT: Androsterone; AOM: Azoxymethane; BA: Bile acids; Bcl-xL: B-cell lymphoma-extra large; BSDC: Bile acid salt sodium deoxycholate; BSEP: Bile salt export pump; BSP: Bone sialoprotein; BTC: Biliary tract cancer; CAC: Colitis-associated cancer; CAF: Cancer-associated fibroblast; CCA: Cholangioca…”
BackgroundGiacomo, S. D., Briz, Ó., Monte, M. J., Sanchez‐Vicente, L., Abete, L., Lozano, E., Mazzanti, G., Sotto, A. D., & Marı́n, J. J. G. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02395-9 · Cited by 67
Ng, K. Y., Chai, S., Tong, M., Guan, X., Lin, C.-H., Ching, Y.-P., Xie, D., Cheng, A. S. L., & Ma, S. (2016) · Oncotarget · doi:10.18632/oncotarget.8209 · Cited by 65
Vaquero, J., Briz, Ó., Herráez, E., Muntané, J., & Marín, J. J. G. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.006 · Cited by 63
Self-citationGarcia, M., Thirouard, L., Sèdes, L., Monrose, M., Holota, H., Caira, F., Volle, D. H., & Beaudoin, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113630 · Cited by 62
“Therefore, activation of Fxrα by non BA ligands was proposed as an attractive strategy to protect against liver and intestinal carcinogenesis, but the mechanism by which FXRα suppresses carcinogenesis remains to be investigated, since FXRα agonists have also been been reported to enhance chemoresistance in colon and l…”
BackgroundMarı́n, J. J. G., Monte, M. J., Macı́as, R. I. R., Romero, M. R., Herráez, E., Asensio, M., Ortiz-Rivero, S., Cives-Losada, C., Giacomo, S. D., González‐Gallego, J., et al. (2022) · Cancers · doi:10.3390/cancers14143524 · Cited by 55
“In addition, short-term exposure in vitro to cisplatin [199] or oxaliplatin and 5-FU [201] results in enhanced MRP3 expression.”
BackgroundSelf-citationMarı́n, J. J. G., Monte, M. J., Blazquez, A. G., Macı́as, R. I. R., Serrano, M. A., & Briz, Ó. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.131 · Cited by 53
Self-citationComprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 56
Namisaki, T., Schaeffeler, E., Fukui, H., Yoshiji, H., Nakajima, Y., Fritz, P., Schwab, M. G., & Nies, A. T. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059832 · Cited by 46
“Previous data have shown that indeed both drug classes may alter membrane transporter expression in cancer cell lines and in clinical samples (Sun et al., 2010; Herraez et al., 2012; Sukowati et al., 2012).”
BackgroundProtective role of biliverdin against bile acid-induced oxidative stress in liver cells
Gonzalez‐Sanchez, E., Perez, M. J., Nytofte, N. S., Briz, Ó., Monte, M. J., Lozano, E., Serrano, M. A., & Marı́n, J. J. G. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.06.016 · Cited by 45
“The primer oligonucleotide sequences and the conditions to carry out QPCR analysis of human BVRα and GAPDH have been described previously [8,20].”
MethodSelf-citationGonzalez‐Sanchez, E., Marı́n, J. J. G., & Perez, M. J. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400732p · Cited by 44
Self-citationMeng, Q., Chen, X., Wang, C., Liu, Q., Sun, H., Sun, P., Huo, X., Liu, Z., Yao, J., & Liu, K. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1727-x · Cited by 48
“It has been demonstrated that Bsep and Shp are direct target genes of FXR and could be induced by FXR in rodent livers (31, 32).”
Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer
Wadhwa, B., Makhdoomi, U. S., Vishwakarma, R. A., & Malik, F. A. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000496 · Cited by 41
Caetano-Pinto, P., Jansen, J., Assaraf, Y. G., & Masereeuw, R. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.01.002 · Cited by 42
Marín, J. J. G., Macías, R. I. R., Monte, M. J., Herráez, E., Peleteiro‐Vigil, A., de Blas, B. S., Sanchon-Sanchez, P., Temprano, Á. G., Espinosa-Escudero, R. A., Lozano, E., et al. (2020) · Cancers · doi:10.3390/cancers12092605 · Cited by 44
“Thus, a markedly increased expression of MRP2 appeared after incubating CRC cells with cisplatin [11,72].”
BackgroundSelf-citationWu, J., Zhu, Y., Guo, Z., Lou, Y.-M., He, S., Yang, G., Zhu, L., Liu, Z., Lu, L., & Liu, L. (2017) · Phytomedicine · doi:10.1016/j.phymed.2017.12.007 · Cited by 37
“…derived from human colon cancer and may serve as suitable in vitro models for testing the effects of xenobiotic drugs on ETs (Arias et al., 2014; Herraez et al., 2012; Schexnayder and Stratford, 2015). tBHQ, a well-known potent Nrf2 activator (Ebert et al., 2007; He et al., 2015), was used as a…”
BackgroundInfluentialInhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells
Seubwai, W., Vaeteewoottacharn, K., Kraiklang, R., Umezawa, K., Okada, S., & Wongkham, S. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504015x14424348426071 · Cited by 32
“A number of studies have shown that ABC transporter expression was induced by anticancer drugs, leading to an unfavorable outcome in many patients (30).”
Gao, X., Fu, T., Wang, C., Ning, C., Kong, Y., Liu, Z., Sun, H., Ma, X., Liu, K., & Meng, Q. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.09.016 · Cited by 36
Martins‐Gomes, C., & Silva, A. M. (2023) · Journal of Xenobiotics · doi:10.3390/jox13020014 · Cited by 32
The Mechanistic Roles of ncRNAs in Promoting and Supporting Chemoresistance of Colorectal Cancer
Micallef, I., & Baron, B. (2021) · Non-Coding RNA · doi:10.3390/ncrna7020024 · Cited by 32
“Furthermore, upregulation of MRP2 and BCRP was also involved in the cisplatin-induced drug resistance in CRC cell lines [137], while overexpression of MRP2 was reported to be responsible for cisplatin resistance in patients undergoing chemotherapy and for OXA resistance in CRC cell lines [138].”
BackgroundRosales, R., Romero, M. R., Vaquero, J., Monte, M. J., Requena, P., Martínez‐Augustin, O., de Medina, F. S., & Marín, J. J. G. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.001 · Cited by 32
Self-citationTocchetti, G. N., Rigalli, J. P., Arana, M. R., Villanueva, S. S. M., & Mottino, A. D. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.05.002 · Cited by 30
Rigalli, J. P., Tocchetti, G. N., & Weiß, J. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170920141707 · Cited by 27
C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells
Xie, C., Pan, Y., Hao, F., Gao, Y., Liu, Z., Zhang, X., Xie, L., Jiang, G., Li, Q., & Wang, E. (2014) · Apmis · doi:10.1111/apm.12296 · Cited by 24
LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2
Liu, B., Guo, Z., Dong, H., Daofeng, T., Cai, Q., Ji, B., Zhang, S., Wu, L., Wang, J., Wang, L., et al. (2015) · Brain Research · doi:10.1016/j.brainres.2015.03.023 · Cited by 24
Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins
Walsh, D. R., Nolin, T. D., & Friedman, P. A. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010728 · Cited by 23
Omondi, R. O., Sibuyi, N. R. S., Fadaka, A. O., Meyer, M., Jaganyi, D., & Ojwach, S. O. (2021) · Dalton Transactions · doi:10.1039/d1dt00412c · Cited by 24
Lajous, H., Riva, R., Lelièvre, B., Tétaud, C., Avril, S., Hindré, F., Boury, F., Jérôme, C., Lecomte, P., & Garcion, E. (2018) · Biomaterials Science · doi:10.1039/c8bm00346g · Cited by 23
Mattia, E. D., Dreussi, E., Cecchin, E., & Toffoli, G. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.214 · Cited by 22
Wu, Y., Liu, L., Zhao, Y., & Zhao, R. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113471 · Cited by 26
Strategies for overcoming ABC transporter-mediated multidrug resistance in colorectal cancer
de Groot, R. A., Reedijk, D., Faucher, Q., Mihaila, S. M., & Masereeuw, R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00412.2025 · Cited by 24
ABC Transporters in Extrahepatic Tissues: Pharmacological Regulation in Heart and Intestine
Villanueva, S. S. M., Zhang, W., Zecchinati, F., Mottino, A. D., & Vore, M. E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180327092639 · Cited by 20
Plasma Membrane Transporters in Modern Liver Pharmacology
Marín, J. J. G. (2012) · Scientifica · doi:10.6064/2012/428139 · Cited by 19
Li, Y., Zhang, X., Zhou, H., Fan, S., Wang, Y., Zhang, L., Liang, J., Wu, X. Y., Wu, H., & Zhang, Y. (2014) · RSC Advances · doi:10.1039/c3ra46920d · Cited by 18
Herráez, E., Sanchez‐Vicente, L., Macı́as, R. I. R., Briz, Ó., & Marı́n, J. J. G. (2017) · Oncotarget · doi:10.18632/oncotarget.16119 · Cited by 17
“The MRP2pr fragments were previously cloned into plasmids to drive the expression of 3’-downstream located firefly luciferase (Luc2) [19].”
InfluentialYangonin protects against estrogen–induced cholestasis in a farnesoid X receptor-dependent manner
Dong, R., Wang, J., Gao, X., Wang, C., Liu, K., Wu, J., Liu, Z., Sun, H., Ma, X., & Meng, Q. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172461 · Cited by 22
Ortiz-Rivero, S., Peleteiro‐Vigil, A., Abete, L., Lozano, E., Hammer, H., Giacomo, S. D., Abad, M., Boix, L., Forner, A., Reig, M., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116038 · Cited by 12
Weissfeld, J. L., Diergaarde, B. B., Nukui, T., Buch, S. C., Pennathur, A., Socinski, M. A., Siegfried, J. M., & Romkes, M. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000262 · Cited by 10
β-catenin as a key regulator of the cisplatin response in tumor cells
Saburi, E., & Moghbeli, M. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01757-1 · Cited by 8
“B-Catenin/TCF/LEF complex upregulates drug resistance genes such as MDR1, MRP1/2, MMPs, CCND1, and BCL-2 [7–9].”
The critical role of circular RNAs in drug resistance in gastrointestinal cancers
Tehrani, S. S., Esmaeili, F., Shirzad, M., Goodarzi, G., Yousefi, T., Maniati, M., Taheri‐Anganeh, M., & Anushiravani, A. (2023) · Medical Oncology · doi:10.1007/s12032-023-01980-4 · Cited by 8
Takeda, F., Oda, M., Terasaki, M., Ichimura, Y., Kojima, H., & Saitoh, H. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115570 · Cited by 7
ABCC2 is involved in the hepatocyte perinuclear barrier for small organic compounds
Rosales, R., Monte, M. J., Blazquez, A. G., Briz, Ó., & Marı́n, J. J. G. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.029 · Cited by 6
MicroRNA-Assisted Hormone Cell Signaling in Colorectal Cancer Resistance
Massaro, C., Safadeh, E., Sgueglia, G., Stunnenberg, H. G., Altucci, L., & Dell’Aversana, C. (2020) · Cells · doi:10.3390/cells10010039 · Cited by 6
“Overexpression of ABC transporters is one of the main mechanisms that gastrointestinal carcinomas exploit toward cisplatin resistance, enforcing the expression of a typical drug-resistance phenotype [34].”
BackgroundSanchez‐Vicente, L., Herráez, E., Briz, Ó., Nogales, R., Molina‐Alcaide, E., & Marín, J. J. G. (2016) · Food Chemistry · doi:10.1016/j.foodchem.2016.02.160 · Cited by 5
Gazaem, M. A. H., Othman, W. N. N. W., Shah, S. A. A., Salihu, M., Zahari, A., Sadiran, S. H., & Salim, F. (2025) · Steroids · doi:10.1016/j.steroids.2025.109584 · Cited by 2
LRIG1 Improves Chemosensitivity Through Inhibition of BCL-2 and MnSOD in Glioblastoma
Ding, J., Liu, B., He, Y., Yuan, X.-H., Tian, D., Ji, B., Wang, L., Wu, L., Dong, H., Wang, J., et al. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0139-6 · Cited by 2
“can reduce the intracellular concentrations of cytotoxic drugs and their metabolites [5–7].”
BackgroundLiver and gastrointestinal cancers
Marín, J. J. G., Macías, R. I. R., Herráez, E., Lozano, E., Romero, M. R., Giacomo, S. D., Efferth, T., & Briz, Ó. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816434-1.00007-3 · Cited by 2
Self-citationWu, Y. C., Xu, Y., Cai, H., Hua, Z., Luo, M., Hu, L., Zhou, N., Wang, X., & Li, W. (2024) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2024.11.002 · Cited by 1
“FXR regulates BA homeostasis and is an important factor in the pathogenesis of cholestasis (Herraez et al., 2012).”
Influence of Sex Hormones on the ABCG2 Transport Protein in Caco-2 Cells
Slepnev, A. A., Abalenikhina, Y. V., Popova, N. M., Shchulkin, A. V., & Yakusheva, E. N. (2023) · Биологические мембраны Журнал мембранной и клеточной биологии · doi:10.31857/s0233475523050109 · Cited by 2
Marín, J. J. G., Blazquez, A. G., Serrano, M. A., Briz, Ó., Monte, M. J., & Macías, R. I. R. (2013) · Wiley eBooks · doi:10.1002/9780470015902.a0025217 · Cited by 1
Self-citationVaquero, J. (2013) · Gredos (University of Salamanca) · doi:10.14201/gredos.121427 · Cited by 2
Self-citationMalviya, R., Singh, A. K., & Yadav, D. (2023) · Wiley eBooks · doi:10.1002/9781394209866.ch6
Effect of Sex Hormones on the ABCG2 Transport Protein in Caco-2 Cells
Slepnev, A. A., Abalenikhina, Y. V., Popova, N. M., Shchulkin, A. V., & Yakusheva, E. N. (2023) · Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology · doi:10.1134/s1990747823050100
Farnesoid X receptor prevents hyperuricemia via activating ATP‐binding cassette subfamily G member 2
Li, R., Tang, G. H., Ye, Y., Chen, G., Lu, L., & Wang, J. (2026) · Rheumatology & autoimmunity · doi:10.1002/rai2.70039
Lin, Z., Wu, R., Yang, Y., Ji, M., Liu, X., Liu, L., & Yang, H. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100282
Peleteiro‐Vigil, A., Ortiz-Rivero, S., Izquierdo-Mateo, Y., Sanchez‐Vicente, L., Gonzalez‐Sanchez, E., Vaquero, J., Arévalo, J. C., Briz, Ó., Monte, M. J., Marı́n, J. J. G., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01881-y
Self-citation
Metadata
- Authors
- Herraez, E., Gonzalez-Sanchez, E., Vaquero, J., Romero, M. R., Serrano, M. A., Marin, J. J. G., & Briz, O.
- Affiliations
- Laboratory of Experimental Hepatology and Drug Targeting (HEVEFARM), Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, Spain
- Universidad de Salamanca (ES)
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-08-01
- Volume
- 9
- Issue
- 9
- Pages
- 2565-2576
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2092149794
- Cited by
- 67
- References
- 42
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 7 · 2015: 5 · 2014: 8 · 2013: 8 · 2012: 2
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Gredos (University of Salamanca) (acceptedVersion, cc-by-nc-nd)
- Hispana (acceptedVersion, cc-by-nc-nd)
- Funders
- Instituto de Salud Carlos III
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- cisplatin, chemoresistance, colon cancer, ABC transporters, MRP2, ABCG2, farnesoid X receptor, SHP, transcriptional activation, HNF4α, HNF1A, FGF19, GW4064, Caco-2 cells, LS174T cells
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 2, Receptor, Farnesoid X-Activated, Cisplatin, Colonic Neoplasms, DNA-Binding Proteins, Humans, Microfilament Proteins, Neoplasm Proteins, Promoter Regions, Genetic, Transcription Factors, Transfection, Transcriptional Activation, Up-Regulation, Gene Expression, Genes, Reporter, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, Caco-2 Cells, Drug Resistance, Neoplasm, Cell Line, Tumor, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.